Index RUT
P/E -
EPS (ttm) -6.51
Insider Own 3.15%
Shs Outstand 156.35M
Perf Week 3.84%
Market Cap 1.29B
Forward P/E 10.18
EPS next Y 0.80
Insider Trans -5.23%
Shs Float 153.96M
Perf Month -0.37%
Income -1002.24M
PEG -
EPS next Q 0.20
Inst Own 105.70%
Short Float 13.74%
Perf Quarter -44.35%
Sales 442.74M
P/S 2.92
EPS this Y 110.57%
Inst Trans -3.31%
Short Ratio 4.66
Perf Half Y -10.47%
Book/sh -2.21
P/B -
EPS next Y 16.99%
ROA -127.54%
Short Interest 21.16M
Perf Year -22.74%
Cash/sh 0.58
P/C 14.01
EPS next 5Y -
ROE -654.88%
52W Range 7.53 - 15.70
Perf YTD -29.02%
Dividend Est. -
P/FCF 7.05
EPS past 5Y -28.37%
ROI -601.74%
52W High -48.28%
Beta 0.55
Dividend TTM -
Quick Ratio 0.84
Sales past 5Y 5.56%
Gross Margin 99.64%
52W Low 7.84%
ATR (14) 0.34
Dividend Ex-Date -
Current Ratio 0.84
EPS Y/Y TTM -668.17%
Oper. Margin 39.17%
RSI (14) 45.77
Volatility 4.59% 3.73%
Employees 267
Debt/Eq -
Sales Y/Y TTM 7.83%
Profit Margin -226.37%
Recom 1.17
Target Price 18.00
Option/Short Yes / Yes
LT Debt/Eq -
EPS Q/Q -102.65%
Payout -
Rel Volume 0.41
Prev Close 8.30
Sales Surprise 0.07%
EPS Surprise -105.00%
Sales Q/Q 9.66%
Earnings May 09 BMO
Avg Volume 4.54M
Price 8.12
SMA20 1.88%
SMA50 -10.57%
SMA200 -21.16%
Trades
Volume 1,863,457
Change -2.17%
Date
Action
Analyst
Rating Change
Price Target Change
Jan-17-24 Initiated
Craig Hallum
Buy
$21
Dec-14-23 Initiated
Wells Fargo
Overweight
$20
Nov-09-23 Initiated
Jefferies
Buy
$21
Sep-28-23 Initiated
JMP Securities
Mkt Outperform
$22
Sep-02-22 Initiated
CapitalOne
Overweight
$15
Apr-22-22 Initiated
Piper Sandler
Overweight
$16
Sep-30-20 Downgrade
Wells Fargo
Overweight → Equal Weight
$14 → $9
Jun-17-20 Initiated
Northland Capital
Outperform
$14
Jul-10-19 Resumed
Credit Suisse
Neutral
Mar-27-19 Upgrade
Morgan Stanley
Underweight → Equal-Weight
Feb-25-19 Upgrade
H.C. Wainwright
Sell → Neutral
$14
Jan-24-19 Upgrade
JP Morgan
Underweight → Neutral
Nov-07-18 Downgrade
JP Morgan
Neutral → Underweight
Nov-07-18 Downgrade
Credit Suisse
Outperform → Neutral
Jul-23-18 Initiated
H.C. Wainwright
Sell
$12.50
May-09-18 Downgrade
Morgan Stanley
Equal-Weight → Underweight
Jan-05-18 Downgrade
BofA/Merrill
Buy → Underperform
Dec-06-17 Downgrade
Mizuho
Buy → Neutral
$16
Jul-21-17 Downgrade
JP Morgan
Overweight → Neutral
May-03-17 Initiated
Wells Fargo
Outperform
Show Previous Ratings
May-02-24 02:33PM
10:01AM
May-01-24 07:30AM
Apr-30-24 01:16PM
Apr-25-24 04:01PM
10:39AM
Loading…
Apr-21-24 10:39AM
Mar-28-24 07:30AM
Mar-05-24 01:05PM
Feb-29-24 04:19PM
(Investor's Business Daily) -37.63%
08:37AM
06:26AM
06:08AM
06:00AM
Feb-23-24 07:30AM
Feb-16-24 10:15AM
09:36AM
Loading…
09:36AM
Feb-15-24 10:45PM
(Thomson Reuters StreetEvents)
08:15AM
07:26AM
(Associated Press Finance)
07:00AM
Feb-05-24 08:50AM
Feb-01-24 04:01PM
Jan-23-24 09:55AM
Jan-08-24 07:00PM
06:00AM
Jan-03-24 04:01PM
Dec-12-23 04:01PM
Nov-30-23 09:45AM
Nov-21-23 04:01PM
Nov-10-23 02:45PM
11:09AM
Loading…
11:09AM
Nov-09-23 10:25PM
(Thomson Reuters StreetEvents)
08:39AM
07:46AM
07:22AM
(Associated Press Finance)
07:00AM
Oct-26-23 04:01PM
Oct-23-23 07:30AM
Oct-17-23 12:02PM
Oct-16-23 06:00AM
Oct-05-23 07:30AM
Oct-03-23 11:43AM
Oct-01-23 07:15AM
Sep-26-23 11:48AM
Sep-20-23 07:36AM
Sep-19-23 12:08PM
11:39AM
Sep-12-23 08:32AM
Sep-07-23 11:30AM
Aug-12-23 08:50AM
Aug-09-23 09:24AM
Aug-08-23 11:12PM
(Thomson Reuters StreetEvents) -9.16%
11:05AM
09:56AM
07:00AM
Jul-28-23 02:56PM
Jul-25-23 04:01PM
Jun-29-23 08:30AM
Jun-21-23 08:00PM
Jun-16-23 07:00AM
Jun-13-23 09:18AM
Jun-12-23 04:05PM
09:54AM
May-25-23 10:32AM
May-23-23 12:07PM
May-22-23 05:43PM
04:08PM
(Investor's Business Daily)
01:11PM
(American City Business Journals)
12:02PM
08:40AM
07:24AM
07:22AM
06:57AM
May-09-23 04:01PM
May-08-23 07:30AM
May-05-23 09:31AM
May-04-23 08:55AM
07:00AM
Apr-26-23 08:00PM
Apr-24-23 07:30AM
Apr-20-23 04:01PM
Mar-22-23 02:53PM
Mar-14-23 02:56AM
Mar-02-23 07:09AM
Feb-27-23 04:01PM
Feb-20-23 07:40AM
Feb-17-23 11:11AM
Feb-16-23 08:35AM
07:00AM
Feb-15-23 11:09AM
Feb-14-23 10:00AM
07:20AM
Feb-13-23 07:30AM
Feb-10-23 07:40AM
Feb-09-23 10:01AM
Feb-04-23 09:40AM
Feb-02-23 04:01PM
Jan-23-23 11:07AM
Jan-16-23 05:36AM
Jan-09-23 06:00AM
Ironwood Pharmaceuticals, Inc. is a healthcare company, which engages in the development and commercialization of Gastrointestinal (GI) products. It operates through the Human Therapeutics segment. The company was founded on January 5, 1998 and is headquartered in Boston, MA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Shetzline Michael CMO,SVP,Head-Res&Drug Mar 08 '24 Option Exercise 0.00 34,936 0 429,847 Mar 12 04:05 PM John Minardo Chief Legal Officer Mar 08 '24 Option Exercise 0.00 32,752 0 311,975 Mar 12 04:05 PM MCCOURT Thomas A Chief Executive Officer Mar 08 '24 Option Exercise 0.00 120,298 0 1,217,948 Mar 12 04:05 PM Davis Andrew SVP, Chief Business Officer Mar 08 '24 Option Exercise 0.00 37,120 0 310,756 Mar 12 04:05 PM Emany Sravan Kumar SVP, Chief Financial Officer Mar 08 '24 Option Exercise 0.00 37,120 0 338,853 Mar 12 04:05 PM Duane Jon R Director Mar 06 '24 Buy 8.70 6,920 60,204 121,028 Mar 08 04:05 PM Emany Sravan Kumar SVP, Chief Financial Officer Mar 04 '24 Buy 9.38 10,684 100,216 301,733 Mar 06 04:05 PM MCCOURT Thomas A Chief Executive Officer Feb 12 '24 Sale 15.24 177,164 2,699,979 832,774 Feb 14 08:35 PM John Minardo Chief Legal Officer Feb 12 '24 Sale 15.24 47,380 722,071 224,796 Feb 14 09:01 PM Shetzline Michael CMO,SVP,Head-Res&Drug Feb 12 '24 Sale 15.24 38,618 588,538 340,484 Feb 14 08:53 PM Davis Andrew SVP, Chief Business Officer Feb 12 '24 Sale 15.24 9,846 150,053 208,324 Feb 14 08:42 PM Silver Ronald Principal Accounting Officer Feb 12 '24 Sale 15.24 7,908 120,518 134,264 Feb 14 08:50 PM Kessler Marla L Director Dec 14 '23 Sale 11.19 9,926 111,072 96,572 Dec 18 04:09 PM Davis Andrew SVP, Chief Business Officer Nov 20 '23 Sale 9.69 3,287 31,851 217,374 Nov 22 04:05 PM Emany Sravan Kumar SVP, Chief Financial Officer Sep 15 '23 Buy 8.32 36,072 300,119 188,730 Sep 18 05:07 PM John Minardo Chief Legal Officer Aug 14 '23 Sale 10.04 7,045 70,732 192,195 Aug 16 04:20 PM Silver Ronald Principal Accounting Officer Aug 14 '23 Sale 10.04 1,976 19,839 134,172 Aug 16 04:21 PM MCCOURT Thomas A Chief Executive Officer May 30 '23 Sale 10.70 26,632 284,962 758,284 Jun 01 05:45 PM MCCOURT Thomas A Chief Executive Officer May 22 '23 Sale 10.12 36,000 364,320 784,916 May 24 04:05 PM Shetzline Michael CMO,SVP,Head-Res&Drug May 22 '23 Sale 10.12 10,324 104,479 321,131 May 24 04:05 PM Davis Andrew SVP, Chief Business Officer May 22 '23 Sale 10.12 6,305 63,807 219,327 May 24 04:05 PM MCCOURT Thomas A Chief Executive Officer May 08 '23 Sale 10.62 21,148 224,592 820,916 May 10 04:05 PM
Index -
P/E -
EPS (ttm) -9.07
Insider Own 27.57%
Shs Outstand 2.47M
Perf Week 0.85%
Market Cap 8.01M
Forward P/E -
EPS next Y -
Insider Trans 0.00%
Shs Float 1.96M
Perf Month -3.75%
Income -21.02M
PEG -
EPS next Q -
Inst Own 39.47%
Short Float 1.03%
Perf Quarter 1.98%
Sales 0.00M
P/S -
EPS this Y -
Inst Trans 20.21%
Short Ratio 6.74
Perf Half Y -8.80%
Book/sh 4.56
P/B 0.65
EPS next Y -
ROA -119.14%
Short Interest 0.02M
Perf Year -53.83%
Cash/sh 2.79
P/C 1.06
EPS next 5Y -
ROE -172.37%
52W Range 1.75 - 6.75
Perf YTD -11.79%
Dividend Est. -
P/FCF -
EPS past 5Y 36.06%
ROI -186.17%
52W High -56.22%
Beta 1.87
Dividend TTM -
Quick Ratio 3.85
Sales past 5Y -33.97%
Gross Margin -
52W Low 68.85%
ATR (14) 0.31
Dividend Ex-Date -
Current Ratio 3.85
EPS Y/Y TTM 55.26%
Oper. Margin 0.00%
RSI (14) 47.48
Volatility 6.82% 7.76%
Employees 1
Debt/Eq 0.00
Sales Y/Y TTM -100.00%
Profit Margin -
Recom 1.00
Target Price 80.00
Option/Short No / Yes
LT Debt/Eq 0.00
EPS Q/Q 79.35%
Payout -
Rel Volume 0.56
Prev Close 2.82
Sales Surprise -13.92%
EPS Surprise -3.33%
Sales Q/Q -100.00%
Earnings -
Avg Volume 2.99K
Price 2.95
SMA20 -5.22%
SMA50 -4.24%
SMA200 -8.15%
Trades
Volume 1,680
Change 4.79%
Date
Action
Analyst
Rating Change
Price Target Change
Oct-20-21 Initiated
Truist
Buy
$14
Sep-24-21 Initiated
Cantor Fitzgerald
Overweight
$7
Jun-03-19 Initiated
Credit Suisse
Neutral
Apr-05-24 06:53AM
Mar-24-24 03:54PM
Dec-04-23 08:00AM
Nov-30-23 06:16PM
Aug-02-23 08:39PM
(American City Business Journals)
07:00AM
Loading…
Jul-31-23 07:00AM
Jun-01-23 04:00PM
May-15-23 01:00PM
May-12-23 02:59PM
May-11-23 06:00PM
06:00PM
Apr-03-23 07:30AM
Mar-27-23 07:00AM
Mar-22-23 04:40PM
Nov-22-22 07:00AM
06:34AM
Loading…
Nov-09-22 06:34AM
Oct-07-22 02:31PM
(American City Business Journals) -9.66%
Oct-06-22 12:46PM
08:00AM
Aug-09-22 05:35PM
04:00PM
Aug-08-22 09:22AM
(Simply Wall St.) +27.76%
Jul-28-22 07:00AM
Jul-26-22 07:00AM
Jun-28-22 09:00AM
Jun-22-22 08:30AM
Jun-17-22 11:20AM
08:00AM
Jun-10-22 07:00AM
Jun-06-22 07:00AM
09:30AM
Loading…
May-11-22 09:30AM
May-04-22 04:01PM
Feb-27-22 06:39AM
Feb-24-22 04:01PM
Feb-23-22 08:00AM
Feb-01-22 05:30AM
Jan-26-22 08:00AM
Dec-15-21 10:00AM
Nov-25-21 04:47AM
Nov-11-21 05:32PM
Nov-09-21 04:01PM
Nov-08-21 12:00PM
(American City Business Journals)
Oct-20-21 04:24PM
Oct-11-21 03:34AM
Oct-10-21 09:37AM
Sep-22-21 08:00AM
Sep-08-21 08:00AM
Aug-26-21 07:19AM
Aug-23-21 05:00PM
Jul-29-21 05:00PM
Jul-22-21 04:30PM
Jul-12-21 02:24AM
Jul-09-21 06:14AM
Jul-08-21 07:22PM
04:30PM
Jun-04-21 10:27AM
08:00AM
08:00AM
May-27-21 04:30PM
May-25-21 07:00AM
May-09-21 03:36AM
Apr-27-21 09:00AM
Apr-26-21 07:00AM
Apr-21-21 07:30AM
Apr-20-21 07:00AM
Mar-24-21 04:05PM
Mar-22-21 02:23AM
Mar-19-21 07:46AM
Mar-18-21 05:00PM
Feb-25-21 07:00AM
Jan-25-21 07:00AM
Jan-21-21 12:52AM
Jan-04-21 07:00AM
Dec-21-20 07:30AM
Dec-02-20 11:27PM
Nov-15-20 07:55AM
Nov-05-20 07:00AM
Oct-14-20 01:09PM
10:07AM
07:00AM
07:00AM
Oct-04-20 09:52AM
Sep-04-20 07:00AM
Aug-25-20 07:00AM
Aug-20-20 11:01AM
Aug-03-20 09:25AM
Jul-30-20 09:00AM
Jul-17-20 07:00AM
Jul-06-20 03:17PM
Jul-05-20 02:45PM
Jun-18-20 04:01PM
May-22-20 07:52AM
Apr-10-20 07:00AM
Mar-23-20 06:50AM
(Simply Wall St.) +18.94%
Jan-13-20 07:00AM
Jan-12-20 05:05PM
Dec-24-19 08:17AM
Dec-23-19 07:00AM
Dec-12-19 03:43PM
Nov-27-19 07:00AM
Cyclerion Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of human therapeutics. Its product pipeline includes several sGC stimulators, small molecules that act synergistically with nitric oxide on sGC to boost production of cyclic guanosine monophosphate. The company was founded on September 6, 2018 and is headquartered in Cambridge, MA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
MCGUIRE TERRANCE Director Aug 09 '23 Sale 3.40 8 27 0 Aug 11 04:25 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite